Presentation (CTI)

OBJECTIVES: To estimate the budget impact of introducing talazoparib for the treatment of adult patients with germline BRCA1/2-mutated, HER2-negative, locally advanced or metastatic breast cancer in Greece.
METHODS: A budget impact model was developed from the perspective of the public payer over a 5-year time horizon to assess the financial consequences of introducing talazoparib into clinical practice. The model compared current and future market share scenarios with and without talazoparib, applying reimbursed treatment costs to the eligible patient population. Patient numbers were estimated using published epidemiological data and local clinical expert’s input. Market share assumptions for scenarios with and without talazoparib were informed by expert experts Drug acquisition, administration, and routine monitoring costs were included and obtained from official Greek healthcare sources (2025 values). The primary outcome was the incremental budget impact associated with the introduction of talazoparib as a treatment option for patients with metastatic breast cancer.
RESULTS: In the current scenario, considering a constant incident number of eligible Greek patients per year total annual treatment costs increased from €98,361 in Year 1 to €158,774 in Year 5, driven primarily by increased utilization of olaparib. In the future scenario, total annual costs reached €224,026 in Year 1 and €245,028 in Year 5, with talazoparib representing the largest cost component. The cumulative 5-year net budget impact was €583,129, corresponding to an average annual budget impact of €116,626.
CONCLUSIONS: The introduction of talazoparib into the Greek reimbursement system is associated with a measurable but manageable increase in pharmaceutical expenditure. The limited budget impact reflects the small eligible patient population resulting from biomarker-based patient selection. These findings may support healthcare resource allocation decisions regarding the use of talazoparib in Greece.